Lim Joo Hyun, Poļaka Inese, Ražuka-Ebela Danute, Bogdanova Inga, Parshutin Sergei, Leja Mārcis, Park Jin Young
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Department of Internal Medicine, Healthcare Research Institute, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, South Korea.
Gastric Cancer. 2025 Jun 16. doi: 10.1007/s10120-025-01629-3.
Although H. pylori is the most important risk factor for gastric cancer, the role of anti-H. pylori antibody titers in gastric carcinogenesis has not been investigated outside Asia. We aimed to analyze the relationship between H. pylori antibody titers and the risk of gastric precancerous lesions in a Caucasian population.
We analyzed the GISTAR pilot study data on participants from Latvia with available anti-H. pylori IgG antibody serology and histopathological information. Participants were classified into four groups according to antibody titer: low-negative (LN), high-negative (HN), low-positive (LP), and high-positive (HP). Odds ratios (ORs) for atrophic gastritis among the 4 groups were compared using logistic regression.
Among a total of 1725 individuals, 970 with available histopathological information were included. A total of 738 individuals (76.1%) had histologically diagnosed atrophic gastritis. Risk of histological atrophic gastritis for each group compared to LN was as follows: HN (OR, 1.52; 95% confidence interval (CI) 0.85-2.72), LP (OR 2.04; 95% CI 1.25-3.32), and HP (OR, 2.47; 95% CI 1.50-4.07). Antibody titer as a continuous variable showed a positive relationship with histological atrophic gastritis (OR 1.09 per 10 EIU; 95% CI 1.04-1.14). The positive relationship was clearer among those aged ≥ 50 years.
Anti-H. pylori antibody titer was positively related to the risk of atrophic gastritis in a middle-aged Caucasian population, suggesting its potential complementary role in gastric cancer risk stratification in a European setting where upper endoscopic examination is less routinely available.
尽管幽门螺杆菌是胃癌最重要的危险因素，但在亚洲以外地区，抗幽门螺杆菌抗体滴度在胃癌发生中的作用尚未得到研究。我们旨在分析白种人群中幽门螺杆菌抗体滴度与胃癌前病变风险之间的关系。
我们分析了来自拉脱维亚的参与者的GISTAR试点研究数据，这些参与者有可用的抗幽门螺杆菌IgG抗体血清学和组织病理学信息。参与者根据抗体滴度分为四组：低阴性（LN）、高阴性（HN）、低阳性（LP）和高阳性（HP）。使用逻辑回归比较四组中萎缩性胃炎的比值比（OR）。
在总共1725名个体中，纳入了970名有可用组织病理学信息的个体。共有738名个体（76.1%）经组织学诊断为萎缩性胃炎。与LN组相比，每组组织学萎缩性胃炎的风险如下：HN组（OR，1.52；95%置信区间（CI）0.85 - 2.72），LP组（OR 2.04；95% CI 1.25 - 3.32），HP组（OR，2.47；95% CI 1.50 - 4.07）。抗体滴度作为连续变量与组织学萎缩性胃炎呈正相关（每10 EIU的OR为1.09；95% CI 1.04 - 1.14）。在年龄≥50岁的人群中，这种正相关关系更明显。
在中年白种人群中，抗幽门螺杆菌抗体滴度与萎缩性胃炎风险呈正相关，这表明在欧洲环境中，在内镜检查不太常规进行的情况下，它在胃癌风险分层中可能具有潜在的补充作用。
